Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition

Elena Beretta, Maria Di Bartolomeo, Roberto Buzzoni, Erminia Ferrario, Luigi Mariani, Arpine Gevorgyan, Emilio Bajetta

Research output: Contribution to journalArticle

Abstract

Aims and background: Irinotecan (CPT-11) has been tested as a single agent in several studies, and response rates of 18-23% have been reported in first-line gastric cancer therapy. In the present study we report the safety and efficacy results combining CPT-11 with 5-fluorouracil (5-FU) and folinic acid (FA). Patients and methods: Thirty consecutive patients with metastatic gastric cancer, considered in poor clinical condition, were treated with CPT-11 and 5-FU/FA according to the FOLFIRI regimen. All enrolled cases were evaluable for toxicity and drug activity. Results: The main grade 3-4 toxicity (according to the NCI-CTC criteria) was neutropenia (16%, grade 4 in 1 patient); non-hematological grade 3 toxicity consisted mainly in vomiting and diarrhea reported in 1 patient. No treatment-related serious adverse events were observed. Response was obtained in 12 patients (40%), stable disease in 2 patients (7%), while progression was documented in 16 patients (53%). Conclusions: These results are very promising, and suggest that the combination of CPT-11 plus 5-FU/FA is active and well tolerated and can be considered as useful treatment in patients with metastatic gastric cancer in poor clinical condition.

Original languageEnglish
Pages (from-to)379-383
Number of pages5
JournalTumori
Volume92
Issue number5
Publication statusPublished - Sep 2006

Keywords

  • Adenocarcinoma
  • Chemotherapy
  • Fluorouracil
  • Irinotecan
  • Metastatic gastric cancer

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition'. Together they form a unique fingerprint.

  • Cite this